by clearskymd | Dec 14, 2020 | Company News
Professor Stephen Smith highlighted the work of ClearSky Medical Diagnostics in diagnosing and monitoring Parkinson’s at a UK–China university consortium in November. The UK-Jiangsu World-Class University Consortium is a group of more than 30 leading...
by clearskymd | Nov 16, 2020 | Company News
ClearSky’s PD-Monitor has been used in a major UK study to investigate whether statins are effective in slowing the progress of Parkinson’s. Statins, such as Simvastatin, are a group of medicines that are currently prescribed to lower cholesterol in the blood....
by clearskymd | Sep 24, 2020 | Company News
ClearSky Medical Diagnostics is recognised as an ‘up and coming’ company tackling neurodegenerative disease through technology. Data science company StartUs Insights, which identifies startups, disruptive technologies and new business models early-on, selected...
by clearskymd | Jul 7, 2020 | Company News
We have launched a new study in China to establish introducing bradykinesia as a feature being measured by LID-Monitor. Parkinson’s is the second most common neurodegenerative disorder and is characterised by bradykinesia – a slowness in carrying out movements....
by clearskymd | Oct 30, 2019 | Company News
ClearSky Medical Diagnostics is thrilled to announce that two LID-Monitors, designed to help people with Parkinson’s control their condition, have been acquired at a hospital in Leeds. Leeds Teaching Hospitals provides a comprehensive service for patients with...
by clearskymd | Jul 2, 2019 | Company News
A research paper describing some of the experimental work being undertaken in the development of ClearSky’s CF-Monitor will be presented at the MedGEC Workshop 2019 in Prague in July. The MedGEC Workshop focusses on the application of genetic and evolutionary...
Recent Comments